{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:33:41Z","timestamp":1760297621408},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2006,4,14]],"date-time":"2006-04-14T00:00:00Z","timestamp":1144972800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Neurooncol"],"published-print":{"date-parts":[[2006,7]]},"DOI":"10.1007\/s11060-005-9095-8","type":"journal-article","created":{"date-parts":[[2006,4,13]],"date-time":"2006-04-13T15:24:42Z","timestamp":1144941882000},"page":"277-280","source":"Crossref","is-referenced-by-count":42,"title":["Vinorelbine combined with a protracted course of temozolomide for recurrent brain Metastases: a phase I trial"],"prefix":"10.1007","volume":"78","author":[{"given":"A.M.","family":"Omuro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.J.","family":"Raizer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Demopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.G.","family":"Malkin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.E.","family":"Abrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2006,4,14]]},"reference":[{"key":"9095_CR1","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s11910-004-0040-6","volume":"4","author":"AM Omuro","year":"2004","unstructured":"Omuro AM, Abrey LE, 2004 Brain metastases Curr Neurol Neurosci Rep 4: 205\u2013210","journal-title":"Curr Neurol Neurosci Rep"},{"key":"9095_CR2","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1023\/A:1012226718323","volume":"53","author":"LE Abrey","year":"2001","unstructured":"Abrey LE, Olson JD, Raizer JJ, et al., 2001 A phase II trial of temozolomide for patients with recurrent or progressive brain metastases J Neurooncol 53:259\u2013265","journal-title":"J Neurooncol"},{"key":"9095_CR3","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1023\/A:1008354323167","volume":"12","author":"C Christodoulou","year":"2001","unstructured":"Christodoulou C, Bafaloukos D, Kosmidis P, et al., 2001 Phase II study of temozolomide in heavily pretreated cancer patients with brain metastases Ann Oncol 12: 249\u2013254","journal-title":"Ann Oncol"},{"key":"9095_CR4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.ijrobp.2004.04.061","volume":"61","author":"E Verger","year":"2005","unstructured":"Verger E, Gil M, Yaya R, et al., 2005 Temozolomide and concomitant whole brain radiotherapy in patients with brain metastases: a phase II randomized trial Int J Radiat Oncol Biol Phys 61: 185\u2013191","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"9095_CR5","doi-asserted-by":"crossref","first-page":"3644","DOI":"10.1200\/JCO.2002.04.140","volume":"20","author":"D Antonadou","year":"2002","unstructured":"Antonadou D, Paraskevaidis M, Sarris G, et al., 2002 Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases J Clin Oncol 20: 3644\u20133650","journal-title":"J Clin Oncol"},{"key":"9095_CR6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1016\/S0959-8049(03)00234-X","volume":"39","author":"R Dziadziuszko","year":"2003","unstructured":"Dziadziuszko R, Ardizzoni A, Postmus PE, et al., 2003 Temozolomide in patients with advanced non-small cell lung cancer with and without brain metastases a phase II study of the EORTC Lung Cancer Group (08965) Eur J Cancer 39: 1271\u20131276","journal-title":"Eur J Cancer"},{"key":"9095_CR7","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2002.20.2.420","volume":"20","author":"D Bafaloukos","year":"2002","unstructured":"Bafaloukos D, Gogas H, Georgoulias V, et al., 2002 Temozolomide in combination with docetaxel in patients with advanced melanoma: a phase II study of the Hellenic Cooperative Oncology Group J Clin Oncol 20: 420\u2013425","journal-title":"J Clin Oncol"},{"key":"9095_CR8","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1016\/S0959-8049(03)00577-X","volume":"39","author":"MJ Bent van den","year":"2003","unstructured":"van den Bent MJ, 2003 The role of chemotherapy in brain metastases Eur J Cancer 39: 2114\u20132120","journal-title":"Eur J Cancer"},{"key":"9095_CR9","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1212\/01.WNL.0000127617.89363.84","volume":"62","author":"W Wick","year":"2004","unstructured":"Wick W, Steinbach JP, Kuker WM, Dichgans J, Bamberg M, Weller M, 2004 One week on\/one week off: A novel active regimen of temozolomide for recurrent glioblastoma Neurology 62: 2113\u20132115","journal-title":"Neurology"},{"key":"9095_CR10","first-page":"3547","volume":"21","author":"DR Macdonald","year":"1990","unstructured":"Macdonald DR, Cascino TL, Schold SC Jr, Cairncross JG, 1990 Response criteria for phase II studies of supratentorial malignant glioma J Clin Oncol 21:3547\u20133549","journal-title":"J Clin Oncol"},{"key":"9095_CR11","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1038\/sj.bjc.6600827","volume":"88","author":"AW Tolcher","year":"2003","unstructured":"Tolcher AW, Gerson SL, Denis L, et al., 2003 Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules Br J Cancer 88: 1004\u20131011","journal-title":"Br J Cancer"},{"key":"9095_CR12","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1212\/01.WNL.0000137050.43114.42","volume":"63","author":"RH Enting","year":"2004","unstructured":"Enting RH, Demopoulos A, DeAngelis LM, Abrey LE, 2004 Salvage therapy for primary CNS lymphoma with a combination of rituximab and temozolomide Neurology 63: 901\u2013903","journal-title":"Neurology"},{"key":"9095_CR13","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1054\/bjoc.2000.1203","volume":"82","author":"RK Gregory","year":"2000","unstructured":"Gregory RK, Smith IE, 2000 Vinorelbine \u2013 a clinical review Br J Cancer 82: 1907\u20131913","journal-title":"Br J Cancer"},{"key":"9095_CR14","first-page":"1367","volume":"43","author":"S Kobayashi","year":"1993","unstructured":"Kobayashi S, Sakai T, Dalrymple PD, Wood SG, Chasseaud LF, 1993 Disposition of the novel anticancer agent vinorelbine ditartrate following intravenous administration in mice, rats and dogs Arzneimittelforschung 43: 1367\u20131377","journal-title":"Arzneimittelforschung"},{"key":"9095_CR15","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1097\/00001813-199602000-00011","volume":"7","author":"C Mouchard-Delmas","year":"1996","unstructured":"Mouchard-Delmas C, Gourdier B, Vistelle R, Wiczewski M, 1996 Modification of the blood\u2013brain barrier permeability by vinorelbine: effect of intracarotid infusion compared with intravenous infusion Anticancer Drugs 7: 213\u2013219","journal-title":"Anticancer Drugs"},{"key":"9095_CR16","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1007\/s00280-003-0632-x","volume":"52","author":"M Donadio","year":"2003","unstructured":"Donadio M, Ardine M, Berruti A, et al., 2003 Gemcitabine and vinorelbine as second-line treatment in patients with metastatic breast cancer: a phase II study Cancer Chemother Pharmacol 52: 147\u2013152","journal-title":"Cancer Chemother Pharmacol"},{"key":"9095_CR17","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1097\/00000421-199706000-00020","volume":"20","author":"M Colleoni","year":"1997","unstructured":"Colleoni M, Graiff C, Nelli P, et al., 1997 Activity of combination chemotherapy in brain metastases from breast and lung adenocarcinoma Am J Clin Oncol 20: 303\u2013307","journal-title":"Am J Clin Oncol"},{"key":"9095_CR18","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1081\/CNV-120001173","volume":"20","author":"G Bernardo","year":"2002","unstructured":"Bernardo G, Cuzzoni Q, Strada MR, et al., 2002 First-line chemotherapy with vinorelbine, gemcitabine, and carboplatin in the treatment of brain metastases from non-small-cell lung cancer: a phase II study Cancer Invest 20: 293\u2013302","journal-title":"Cancer Invest"},{"key":"9095_CR19","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/S0169-5002(99)00071-9","volume":"26","author":"X Quantin","year":"1999","unstructured":"Quantin X, Khial F, Reme-Saumon M, Michel FB, Pujol JL, 1999 Concomitant brain radiotherapy and vinorelbine\u2013ifosfamide\u2013cisplatin chemotherapy in brain metastases of non-small cell lung cancer Lung Cancer 26: 35\u201339","journal-title":"Lung Cancer"},{"key":"9095_CR20","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1159\/000066520","volume":"64","author":"J Cortes","year":"2003","unstructured":"Cortes J, Rodriguez J, Aramendia JM, et al., 2003 Front-line paclitaxel\/cisplatin-based chemotherapy in brain metastases from non-small-cell lung cancer Oncology 64: 28\u201335","journal-title":"Oncology"},{"key":"9095_CR21","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1023\/A:1008338312647","volume":"12","author":"G Robinet","year":"2001","unstructured":"Robinet G, Thomas P, Breton JL, et al., 2001 Results of a phase III study of early versus delayed whole brain radiotherapy with concurrent cisplatin and vinorelbine combination in inoperable brain metastasis of non-small-cell lung cancer: Groupe Francais de Pneumo-Cancerologie (GFPC) Protocol 95\u20131 Ann Oncol 12: 59\u201367","journal-title":"Ann Oncol"},{"key":"9095_CR22","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1056\/NEJMe058007","volume":"352","author":"R Kurzrock","year":"2005","unstructured":"Kurzrock R, Benjamin RS, 2005 Risks and benefits of phase 1 oncology trials, revisited N Engl J Med 352: 930\u2013932","journal-title":"N Engl J Med"},{"key":"9095_CR23","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMsa042220","volume":"352","author":"E Horstmann","year":"2005","unstructured":"Horstmann E, McCabe MS, Grochow L, et al., 2005 Risks and benefits of phase 1 oncology trials, 1991 through 2002 N Engl J Med 352: 895\u2013904","journal-title":"N Engl J Med"}],"container-title":["Journal of Neuro-Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-005-9095-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11060-005-9095-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11060-005-9095-8","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,1]],"date-time":"2019-06-01T04:18:53Z","timestamp":1559362733000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11060-005-9095-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,4,14]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2006,7]]}},"alternative-id":["9095"],"URL":"https:\/\/doi.org\/10.1007\/s11060-005-9095-8","relation":{},"ISSN":["0167-594X","1573-7373"],"issn-type":[{"value":"0167-594X","type":"print"},{"value":"1573-7373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,4,14]]}}}